Literature DB >> 24713114

Serotonergic, noradrenergic and dopaminergic markers are related to cognitive function in adults with 22q11 deletion syndrome.

Laurens J M Evers1, Leopold M G Curfs2, Jaap A Bakker3, Erik Boot4, Fabiana da Silva Alves5, Nico Abeling6, Jörgen Bierau3, Marjan Drukker7, Therese A M J van Amelsvoort7.   

Abstract

Patients with 22q11 deletion syndrome (22q11DS) have a high prevalence of psychiatric disorders and intellectual disability. At present the neurobiology underlying psychopathology in 22q11DS is still not understood. In the present study, we analyzed urinary serotonergic, dopaminergic and noradrenergic markers in 67 adults with 22q11DS. Levels of serotonin and the catecholamine metabolite homovanillic acid were significantly lower in the 22q11DS subjects compared to healthy controls. Within the 22q11DS group, levels of dopamine, homovanillic acid, norepinephrine, vanillyl mandelic acid and serotonin positively correlated with Full Scale Intelligence Quotient scores. Our results suggest that cognitive deficits in 22q11DS are associated with abnormal function of several neurotransmitters.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24713114     DOI： 10.1017/S1461145714000376

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN： 1461-1457            Impact factor:   5.176


  8 in total

Review 1.  Neurobiological perspective of 22q11.2 deletion syndrome.

Authors:  Janneke R Zinkstok; Erik Boot; Anne S Bassett; Noboru Hiroi; Nancy J Butcher; Claudia Vingerhoets; Jacob A S Vorstman; Therese A M J van Amelsvoort
Journal:  Lancet Psychiatry       Date:  2019-08-05       Impact factor: 27.083

Review 2.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

Review 3.  Developmental trajectories in 22q11.2 deletion.

Authors:  Ann Swillen; Donna McDonald-McGinn
Journal:  Am J Med Genet C Semin Med Genet       Date:  2015-05-18       Impact factor: 3.908

Review 4.  The importance of understanding cognitive trajectories: the case of 22q11.2 deletion syndrome.

Authors:  Ann Swillen
Journal:  Curr Opin Psychiatry       Date:  2016-03       Impact factor: 4.741

5.  Glutamatergic markers, age, intellectual functioning and psychosis in 22q11 deletion syndrome.

Authors:  Laurens J M Evers; Therese A M J van Amelsvoort; Jaap A Bakker; Mariken de Koning; Marjan Drukker; Leopold M G Curfs
Journal:  Psychopharmacology (Berl)       Date:  2015-06-10       Impact factor: 4.530

Review 6.  The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review.

Authors:  Vladimir Maletic; Anna Eramo; Keva Gwin; Steve J Offord; Ruth A Duffy
Journal:  Front Psychiatry       Date:  2017-03-17       Impact factor: 4.157

7.  Lower [18F]fallypride binding to dopamine D2/3 receptors in frontal brain areas in adults with 22q11.2 deletion syndrome: a positron emission tomography study.

Authors:  Esther D A van Duin; Jenny Ceccarini; Jan Booij; Zuzana Kasanova; Claudia Vingerhoets; Jytte van Huijstee; Alexander Heinzel; Siamak Mohammadkhani-Shali; Oliver Winz; Felix Mottaghy; Inez Myin-Germeys; Thérèse van Amelsvoort
Journal:  Psychol Med       Date:  2019-04-02       Impact factor: 7.723

8.  Neural correlates of reward processing in adults with 22q11 deletion syndrome.

Authors:  Esther D A van Duin; Liesbet Goossens; Dennis Hernaus; Fabiana da Silva Alves; Nicole Schmitz; Koen Schruers; Therese van Amelsvoort
Journal:  J Neurodev Disord       Date:  2016-07-15       Impact factor: 4.025
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.